News MSD said to have pulled back from Revolution Meds deal Negotiations between MSD and Revolution Medicines over a possible $30bn takeover of Revolution Medicines have reportedly collapsed.
News Report says MSD is in talks to buy Revolution Meds MSD is rumoured to be in talks to buy Revolution Medicines and its KRAS inhibitor pipeline in a deal that could be worth up to $32 billion.
News Another LAG-3 setback as Regeneron drug fails phase 3 trial Regeneron's LAG-3 inhibitor fianlimab has missed the mark in a highly anticipated melanoma trial, hitting its share price.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
